(INTS) Intensity Therapeutics, Inc. Business Model Canvas Research

Ontario Institute for Cancer Research is a partner in Intensity Therapeutics, Inc.'s Phase II neoadjuvant breast cancer study, adding trial-design depth and translational research support. That matters in a program that can be powered by only a few dozen patients, where even small design gains can improve signal quality and credibility.

The collaboration also adds institutional trust to the clinical program, which can help with investigator reach and future funding discussions.

• Phase II breast cancer study support
• Better trial design and translation
• Stronger clinical credibility

Intensity Therapeutics, Inc. relies on oncology investigators and trial sites to enroll, treat, and follow patients in its Phase 2 studies across multiple solid tumors, where human safety and efficacy data are the main value driver. In 2025, the company reported active clinical development in this stage, and each site matters because small Phase 2 cohorts can still produce decision-grade data faster than larger late-stage trials.

• Enroll patients
• Track safety data
• Run Phase 2 sites

Intensity Therapeutics, Inc. lives on clinical data generation and analysis: it tracks safety and tumor response from each trial patient to decide whether an indication moves forward or stops. This readout also shapes partner talks and future FDA planning, which is critical for a clinical-stage company that still has no product sales and must prove value trial by trial.

• Safety data drives go/no-go calls.

• Response data supports partner talks.

• Trial results guide regulatory planning.

Intensity Therapeutics focuses on discovering and advancing therapies for solid tumors, a market that represents about 90% of adult cancers. Its work is not just lab research; it also includes long-term commercialization planning, with partnership talks and launch prep starting before approval so the company can move faster if a program succeeds.

• Solid tumors: ~90% of adult cancers
• Research plus launch planning
• Partnering begins before approval

Intensity Therapeutics, Inc. relies on an academic research network anchored by The Ottawa Hospital Research Institute and the Ontario Institute for Cancer Research, which supply clinical trial infrastructure and oncology know-how. That setup helps run complex cancer studies, especially when tight patient screening, protocol control, and translational science need to move in sync.

• Trial infrastructure at both institutes
• Scientific expertise in oncology
• Supports complex study execution

Intensity Therapeutics, Inc. is headquartered in Westport, Connecticut, where the site supports corporate, scientific, and administrative work for the clinical-stage company founded in 2012. It anchors a lean base for trial operations and decision-making as the company advances its pipeline.

• Westport HQ: corporate, science, admin
• Founded in 2012
• Clinical-stage base

As a key resource, the headquarters keeps core teams close, which helps coordinate research, financing, and regulatory tasks from one location.

Intensity Therapeutics, Inc. is pursuing INT230-6 across several solid tumors, and that breadth matters because solid tumors make up about 90% of adult cancers. If one program works, the same local-delivery platform can be tested across more than one patient group, widening the addressable market and speeding clinical learning.

• Multiple tumor types, one platform
• Broader market if efficacy holds
• Cross-population learning improves data

Intensity Therapeutics, Inc. tests INT230-6 in the Ottawa and Ontario collaboration before surgery in early-stage breast cancer. Neoadjuvant use can prove value fast if it shrinks the primary tumor, and that could move INT230-6 beyond advanced disease into a larger, earlier treatment setting.

• Before-surgery testing

• Tumor response drives value

• Opens early-stage use

Patients are the core of Intensity Therapeutics, Inc.’s trial relationship: Phase 2 oncology studies usually enroll tens to a few hundred participants, and completion depends on trust, clear informed consent, and tight safety follow-up. With cancer trials, even one missed visit or adverse event report can hurt retention, so patient-centered communication is not optional.

• Phase 2 relies on patient enrollment.
• Consent and safety checks drive trust.
• Follow-up supports trial completion.

Scientific communication at Intensity Therapeutics, Inc. depends on clear, timely trial updates. Clinical-stage biotech firms keep partners aligned through study reports, investor updates, and research talks, which helps preserve trust and momentum while data are still evolving.

• Share results fast
• Use study reports
• Keep stakeholders aligned

Scientific and medical conferences are a key visibility channel for Intensity Therapeutics, Inc. Clinical-stage oncology firms use meetings like ASCO, ESMO, and AACR to show early trial data to investigators, partners, and investors; ASCO alone drew 40,000+ attendees in 2025, giving results wide reach. This helps turn early signals into market awareness fast.

• Shows trial progress early
• Reaches 40,000+ ASCO attendees
• Supports partner and investor interest

As a public company, Intensity Therapeutics uses SEC filings, earnings releases, and investor updates to reach capital markets, support funding, and build partnership awareness. This channel matters before launch because it shapes visibility with investors while the company advances its pipeline and needs capital to keep operating.

• Reaches investors and analysts
• Supports funding and partnerships
• Builds trust before launch

Women with early-stage breast cancer are Intensity Therapeutics, Inc.’s core customer segment for its randomized Phase II neoadjuvant study, which targets women diagnosed before the disease becomes advanced. This use case is distinct because neoadjuvant therapy is meant to shrink tumors before surgery, not treat metastatic disease; breast cancer remains the most common cancer in women worldwide, with about 2.3 million new cases each year.

• Early-stage, pre-surgery patients
• Phase II randomized study focus
• Different from advanced cancer use

Oncology physicians, hospitals, and research centers are Intensity Therapeutics, Inc.'s trial execution customers: they screen and enroll patients, give treatment, and collect endpoint data. Their participation is mandatory in every clinical program, and access to oncology sites matters because cancer trials depend on fast accrual and tight data capture.

• Enroll patients for each study
• Administer treatment and track safety
• Collect data for regulatory review

Intensity Therapeutics, Inc. keeps general and administrative expenses high because Westport, Connecticut headquarters support management, finance, legal, and compliance work. As a public company, it also pays for SEC reporting, audit, board oversight, and investor relations, so this cost line stays material even before sales scale.

• Westport HQ drives corporate overhead.
• Management, finance, legal, compliance.
• Public-company reporting adds fixed costs.

Regulatory and manufacturing support covers CMC work, IND filings, and investigational drug supply for Intensity Therapeutics, Inc. As trials move from early to later stages, these costs usually climb because batch production, quality testing, and regulatory updates expand with each new cohort and site.

• CMC work supports trial-grade supply
• IND and amendment filings add cost
• Later-stage trials raise spend fast

If INT230-6 succeeds, Intensity Therapeutics, Inc. could earn licensing fees plus low-single-digit to mid-single-digit royalties, a standard biotech deal path. That income is still contingent on clinical proof, FDA progress, and a partner willing to fund late-stage development and launch.

• Royalties need clinical success.
• Partner interest drives deal terms.
• Commercial sales must begin first.

Intensity Therapeutics, Inc. is still a clinical-stage Company, so 2025 revenue from product sales was 0. If INT230-6 wins approval, future sales would come from solid tumor uses, giving the Company a long-term revenue base tied to oncology demand.

• No commercial sales yet
• Revenue starts after approval
• Solid tumors are the target market